PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023

preview_player
Показать описание
Explore the recent developments and clinical updates on PARP inhibitors in the management of ovarian cancer.

With Dr Susana Banerjee, Dr Domenica Lorusso and Prof. Frederik Marme.

--------
This activity is funded by an independent medical education grant from GlaxoSmithKline and is provided by touchIME.
  1. Touch Medical Media
Рекомендации по теме
PARP inhibitors in 0:59:14

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023

What’s New with 0:58:44

What’s New with PARP Inhibitors and Ovarian Cancer?

PARP inhibitors for 0:03:45

PARP inhibitors for ovarian cancer

Overcoming resistance to 0:01:22

Overcoming resistance to PARP inhibition in ovarian cancer

An Overview of 0:03:05

An Overview of PARP Inhibitors in Ovarian Cancer

PARP Inhibitors for 0:01:26

PARP Inhibitors for Maintenance Therapy in Ovarian Cancer

Personalizing Advanced Ovarian 0:57:11

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel Approaches

PARP Inhibition Improves 0:01:27

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer

Updates in PARP 0:01:38

Updates in PARP inhibition for ovarian cancer

PARP Inhibitors for 0:34:17

PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat

Recurrent Ovarian Cancer: 0:03:06

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

Assessing the role 0:02:38

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancer

PARP inhibitor rechallenging 0:00:46

PARP inhibitor rechallenging in ovarian cancer

Ovarian Cancer: Comparisons 0:07:09

Ovarian Cancer: Comparisons Between PARP Inhibitors

PARP Inhibitor Side 0:06:35

PARP Inhibitor Side Effect Management in Ovarian Cancer

Adverse-Effect Profiles of 0:05:53

Adverse-Effect Profiles of PARP Inhibitors in Ovarian Cancer

SOLO-1 and PARP 0:04:40

SOLO-1 and PARP Inhibitors in Ovarian Cancer

Dr. Liu on 0:01:47

Dr. Liu on PARP Inhibitors in Recurrent Ovarian Cancer

PARP Inhibitors in 0:06:20

PARP Inhibitors in Recurrent Ovarian Cancer

The promising potential 0:03:09

The promising potential of PARP inhibitors in ovarian cancer

PARP Inhibitors in 0:11:05

PARP Inhibitors in Recurrent Ovarian Cancer

Dr. Penson on 0:01:30

Dr. Penson on Research With PARP Inhibitors in Ovarian Cancer

PARP Inhibition in 0:06:21

PARP Inhibition in BRCA1/2+ or HRD- Ovarian Cancer

Dr. Campos on 0:00:59

Dr. Campos on Next Steps With PARP Inhibitors in Ovarian Cancer

Комментарии
Автор

I think it is worth pointing out that you had said IDS/NAC is worse than PDS via GORILLA-3004. Which states this is true for non-BRCAm patients. In BRCAm patients, the only independent risk factor found was CA-125>26/4U/mL. Just saying the blanket statement in the video is a bit misleading.

gwailo